BRPI0814260B8 - composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero - Google Patents

composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero

Info

Publication number
BRPI0814260B8
BRPI0814260B8 BRPI0814260A BRPI0814260A BRPI0814260B8 BR PI0814260 B8 BRPI0814260 B8 BR PI0814260B8 BR PI0814260 A BRPI0814260 A BR PI0814260A BR PI0814260 A BRPI0814260 A BR PI0814260A BR PI0814260 B8 BRPI0814260 B8 BR PI0814260B8
Authority
BR
Brazil
Prior art keywords
polymer
polymers
composition
stranded
contacting
Prior art date
Application number
BRPI0814260A
Other languages
English (en)
Portuguese (pt)
Inventor
Heinz Vollmer Jorg
Jurk Marion
Original Assignee
Coley Pharm Gmbh
Pfizer Animal Health S A
Zoetis Belgium S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814260(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coley Pharm Gmbh, Pfizer Animal Health S A, Zoetis Belgium S A filed Critical Coley Pharm Gmbh
Publication of BRPI0814260A2 publication Critical patent/BRPI0814260A2/pt
Publication of BRPI0814260B1 publication Critical patent/BRPI0814260B1/pt
Publication of BRPI0814260B8 publication Critical patent/BRPI0814260B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
BRPI0814260A 2007-08-13 2008-08-08 composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero BRPI0814260B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96444807P 2007-08-13 2007-08-13
PCT/IB2008/002104 WO2009022216A2 (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles

Publications (3)

Publication Number Publication Date
BRPI0814260A2 BRPI0814260A2 (pt) 2015-03-31
BRPI0814260B1 BRPI0814260B1 (pt) 2019-11-12
BRPI0814260B8 true BRPI0814260B8 (pt) 2021-05-25

Family

ID=40351228

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814260A BRPI0814260B8 (pt) 2007-08-13 2008-08-08 composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero

Country Status (22)

Country Link
US (3) US8128944B2 (enExample)
EP (1) EP2179039B1 (enExample)
JP (1) JP4847609B2 (enExample)
KR (1) KR20100045508A (enExample)
CN (1) CN101821392B (enExample)
AR (1) AR067928A1 (enExample)
AU (1) AU2008288241B2 (enExample)
BR (1) BRPI0814260B8 (enExample)
CA (1) CA2696630C (enExample)
CL (1) CL2008002371A1 (enExample)
CO (1) CO6260153A2 (enExample)
DK (1) DK2179039T3 (enExample)
ES (1) ES2703876T3 (enExample)
MX (1) MX2010001014A (enExample)
NZ (1) NZ582972A (enExample)
PL (1) PL2179039T3 (enExample)
PT (1) PT2179039T (enExample)
RU (1) RU2435851C2 (enExample)
SI (1) SI2179039T1 (enExample)
TR (1) TR201820474T4 (enExample)
TW (1) TW200916106A (enExample)
WO (1) WO2009022216A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4847609B2 (ja) 2007-08-13 2011-12-28 コーリー ファーマシューティカル ゲーエムベーハー 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ
JP2010536907A (ja) * 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
WO2013012875A2 (en) 2011-07-18 2013-01-24 Mount Sinai School Of Medicine Bacterial rnas as vaccine adjuvants
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3220895B1 (en) 2014-11-21 2022-08-31 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
MX2020006243A (es) 2017-12-15 2020-09-03 Bayer Animal Health Gmbh Oligonucleotidos inmunoestimulantes.
WO2024030844A1 (en) * 2022-08-01 2024-02-08 University Of Mississippi Choline carboxylic acid based ionic liquids as antimicrobial agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
IL112920A (en) * 1994-03-07 2003-04-10 Dow Chemical Co Composition comprising a dendritic polymer complexed with at least one unit of biological response modifier and a process for the preparation thereof
ID29546A (id) * 1999-02-15 2001-09-06 Nippon Shinyaku Co Ltd Polinukleotida dengan rantai yang diperpendek dan metode pembuatannya
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
RU2289410C2 (ru) * 2001-04-04 2006-12-20 Корикса Корпорейшн Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах
RU2185818C1 (ru) * 2001-07-10 2002-07-27 НИИ "Молекулярной медицины" Московской медицинской академии им. И.М. Сеченова Композиция для лечения легочных инфекций
IL160157A0 (en) * 2001-08-17 2004-07-25 Coley Pharm Group Inc Combination motif immune stimulation oligonucleotides with improved activity
EP1499187B1 (en) * 2002-04-04 2015-06-17 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
CN1302948C (zh) 2002-04-12 2007-03-07 爱信艾达株式会社 车载装置用电源管理系统
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US7956043B2 (en) * 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
AU2004259204B2 (en) * 2003-07-15 2010-08-19 Idera Pharmaceuticals, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
CA2555390C (en) * 2004-02-19 2014-08-05 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US8076068B2 (en) * 2005-09-14 2011-12-13 Gunther Hartmann Method for determining immunostimulatory activity of RNA oligonucleotides
ES2536103T3 (es) * 2005-11-25 2015-05-20 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimuladores
JP4847609B2 (ja) * 2007-08-13 2011-12-28 コーリー ファーマシューティカル ゲーエムベーハー 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ

Also Published As

Publication number Publication date
JP2010536739A (ja) 2010-12-02
MX2010001014A (es) 2010-03-01
PL2179039T3 (pl) 2019-03-29
DK2179039T3 (en) 2019-01-07
WO2009022216A3 (en) 2009-06-04
BRPI0814260A2 (pt) 2015-03-31
EP2179039A2 (en) 2010-04-28
US8227447B2 (en) 2012-07-24
CN101821392A (zh) 2010-09-01
RU2435851C2 (ru) 2011-12-10
CL2008002371A1 (es) 2009-07-03
CO6260153A2 (es) 2011-03-22
HK1143741A1 (en) 2011-01-14
CA2696630C (en) 2014-04-01
RU2010104618A (ru) 2011-09-20
AR067928A1 (es) 2009-10-28
WO2009022216A9 (en) 2009-04-30
CN101821392B (zh) 2013-04-17
CA2696630A1 (en) 2009-02-19
US20120258140A1 (en) 2012-10-11
PT2179039T (pt) 2019-01-11
WO2009022216A2 (en) 2009-02-19
US20100272785A1 (en) 2010-10-28
TR201820474T4 (tr) 2019-01-21
SI2179039T1 (sl) 2019-01-31
AU2008288241A1 (en) 2009-02-19
US8128944B2 (en) 2012-03-06
US20120121648A1 (en) 2012-05-17
NZ582972A (en) 2011-09-30
TW200916106A (en) 2009-04-16
BRPI0814260B1 (pt) 2019-11-12
US8466124B2 (en) 2013-06-18
KR20100045508A (ko) 2010-05-03
ES2703876T3 (es) 2019-03-12
AU2008288241B2 (en) 2011-12-01
JP4847609B2 (ja) 2011-12-28
EP2179039B1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
BRPI0814260B8 (pt) composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero
WO2020178162A8 (en) Exocyclic amine substituted coumarin compounds and their uses as fluorescent labels
ZA202213353B (en) Substituted coumarin dyes and uses as fluorescent labels
ZA202007843B (en) Tertiary amine substituted coumarin compounds and their uses as fluorescent labels
MX2022009280A (es) Vacunas de arn contra el coronavirus.
EP4257596A3 (en) Coumarin compounds and their uses as fluorescent labels
BRPI0819526B8 (pt) Sequência de ácido nucleico de precursor de mirna artificial, construção recombinante e método para reduzir a expressão de uma sequência alvo
BR112018007982A2 (pt) composição, reação enzimática e método para preparar um copolímero de enxerto
BR112016013148A2 (pt) "composições de rnai de componente do complemento e métodos de utilização das mesmas
BR112015022507A2 (pt) ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados
CO6300833A2 (es) Composiciones de agente espesante que contienen alternano y un polisacarido para productos alimentarios
BRPI0924653B8 (pt) composto de ferro-oligossacarídeo, composição e uso de deste composto
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
IN2014DN07197A (enExample)
BRPI0707493B8 (pt) composto inibidor de enzimas e1 ativadoras e composição farmacêutica contendo o referido composto
MX2009009530A (es) Composiciones de acidos nucleicos cerrados bicatenarios.
BR112013024609A8 (pt) cultura biologicamente pura de bradyrhizobia japonicum, cepa de bradyrhizobium, composição, e, método para intensificar o crescimento da planta
BR112012020628A2 (pt) fotoiniciador de éter polialquílico, uso de um fotoiniciador de éter polialquílico, método para curar uma composição de matriz, e, composição de matriz
BR112012003560A8 (pt) bebida alcoólica, método de produção de uma bebida alcoólica e composição farmacêutica
BRPI0821034A8 (pt) Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação
MY203259A (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
BRPI0909737A2 (pt) compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos
FR2932489B1 (fr) Composition renfermant un polymere (meth)acrylique et un copolymere porteur de groupes associatifs
MX2011008542A (es) Molecula de acido nucleico de un racimo biosintetico que codifica sintasas peptidicas no ribosomales y usos de la misma.
CL2008003820A1 (es) Metodo para producir el virus de estomatitis vesicular atenuado (vsv) en un cultivo celular que comprende introducir en un vector el gen vsv g optimizado; composicion inmunogenica que comprende el vsv atenuado; kit para producir el vsv.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PFIZER ANIMAL HEALTH S.A. (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS BELGIUM S.A. (BE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF